Cytokinetics to Host Investor Breakfast and Webcast Following Presentation of Results from BENEFIT-ALS
South San Francisco, CA, April 23, 2014 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that it plans to host an Investor Breakfast and Webcast on the morning following the presentation of the results from the BENEFIT-ALS trial at the 66th Annual Meeting of the American Academy of Neurology. The Cytokinetics sponsored event will be held on Wednesday, April 30th from 7:00 AM - 9:00 AM Eastern Time in the Grand Ballroom of the Ritz Carlton Hotel, Philadelphia, PA. The formal program and webcast will begin at 7:30 AM Eastern Time.
Cytokinetics will be represented by Robert I. Blum, President and Chief Executive Officer; Dr. Andrew A. Wolff, Senior Vice President of Clinical Research and Development and Chief Medical Officer; Dr. Fady I. Malik, Senior Vice President, Research and Early Development; and Dr. Jinsy Andrews, Director of Clinical Research and Medical Monitor of BENEFIT-ALS. Also participating will be Dr. Jeremy M. Shefner, Professor and Chair, Department of Neurology at the Upstate Medical University, State University of New York and Principal Investigator of BENEFIT-ALS; Dr. Robert G. Miller, Clinical Professor of Neurology and Neurological Sciences at Stanford University, and Director of the Forbes Norris ALS Research Center at the California Pacific Medical Center; and Dr. Merit E. Cudkowicz, Professor of Neurology, Harvard Medical School and Chief of Neurology Service at Massachusetts General Hospital (MGH) and Director of the ALS Clinic at MGH.
Those interested in attending in person should RSVP to email@example.com by April 25, 2014. In addition, others may access the live webcast of the presentation and accompanying slides by visiting the Investor Relations section of Cytokinetics' website at www.cytokinetics.com. The live audio of the forum will also be accessible by dialing either (866) 999-2985 (United States and Canada) or (706) 679-3078 (International) and typing in the passcode 28937827. The webcast replay of the presentation will be archived on the Presentations page within the Investor Relations section of Cytokinetics' website following the event. The replay will also be available via telephone from April 30, 2014 at 1:00 PM Eastern Time until May 7, 2014 by dialing (855) 859-2056 (United States and Canada) or (404) 537-3406 (International) and typing in the passcode 28937827.
Cytokinetics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. Cytokinetics' lead drug candidate from its cardiac muscle contractility program, omecamtiv mecarbil, is in Phase II clinical development for the potential treatment of heart failure. Amgen Inc. holds an exclusive license worldwide to develop and commercialize omecamtiv mecarbil and related compounds, subject to Cytokinetics' specified development and commercialization participation rights. Cytokinetics is independently developing tirasemtiv, a fast skeletal muscle activator, as a potential treatment for diseases and medical conditions associated with neuromuscular dysfunction. Tirasemtiv is currently the subject of a Phase II clinical trials program and has been granted orphan drug designation and fast track status by the U.S. Food and Drug Administration and orphan medicinal product designation by the European Medicines Agency for the potential treatment of amyotrophic lateral sclerosis (ALS). Cytokinetics is collaborating with Astellas Pharma Inc. to develop CK-2127107, a skeletal muscle activator structurally distinct from tirasemtiv, for non-neuromuscular indications. All of these drug candidates have arisen from Cytokinetics' muscle biology focused research activities and are directed towards the cytoskeleton. The cytoskeleton is a complex biological infrastructure that plays a fundamental role within every human cell. Additional information about Cytokinetics can be obtained at www.cytokinetics.com.
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Act's safe harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to planned presentations, and the properties and potential benefits of Cytokinetics' drug candidates and potential drug candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in the development, testing, regulatory approval and production of Cytokinetics' drug candidates and potential drug candidates that could slow or prevent clinical development or product approval, including risks that current and past results of clinical trials or preclinical studies may not be indicative of future clinical trials results and that Cytokinetics' drug candidates and potential drug candidates may have unexpected adverse side effects or inadequate therapeutic efficacy. For further information regarding these and other risks related to Cytokinetics' business, investors should consult Cytokinetics' filings with the Securities and Exchange Commission.
Joanna L. Goldstein
Manager, Investor Relations & Corporate Communications